Previous 10 | Next 10 |
‒ Q1 2021 Net Revenue of $493 million; GAAP Net Income of $7 million; Diluted Income per Share of $0.04 ‒ ‒ Adjusted EBITDA (1) of $126 million; Adjusted Diluted EPS (1) of $0.20 ‒ ‒ Maintaining 2021 Full Year Financial Ou...
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its first quarter 2021 financial results on Friday, May 7, 2021, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time...
Amneal Pharmaceuticals, Inc. (the “ Company ”) (NYSE: AMRX) and Kashiv BioSciences LLC (“ Kashiv ”) today announced that Amneal Pharmaceuticals LLC (“ Amneal ”), a subsidiary of the Company, has completed its previously announced acq...
Not your typical March as the month came 'in like a lamb, and out like a lion.' No, we aren’t discussing precipitation in March, but the precipitous equity market behavior for the U.S stock market on the precipice of all-time highs and what that means for the top stocks moving into Apr...
Today, we take our first look at a small developmental biotech concern named Amneal Pharmaceuticals. The company came public in the first half of 2018 and is deep in "Busted IPO" territory. The shares have become a battleground stock within the analyst community. A full analys...
Image source: The Motley Fool. Amneal Pharmaceuticals, Inc. (NYSE: AMRX) Q4 2020 Earnings Call Feb 26, 2021 , 8:30 a.m. ET Operator Continue reading For further details see: Amneal Pharmaceuticals, Inc. (AMRX) Q4 2020 Earnings Call Transc...
Amneal Pharmaceuticals, Inc. (AMRX) Q4 2020 Earnings Conference Call February 26, 2021 8:30 AM ET Company Participants Tasos Konidaris - Chief Financial Officer Chirag Patel - Co-Chief Executive Officer Chintu Patel - Co-Chief Executive Officer Joe Todisco - Chief Commercial Officers of Gener...
The following slide deck was published by Amneal Pharmaceuticals, Inc. in conjunction with their 2020 Q4 earnings call. For further details see: Amneal Pharmaceuticals, Inc. 2020 Q4 - Results - Earnings Call Presentation
Amneal Pharmaceuticals (AMRX) shares rise nearly 5% premarket after posting fourth-quarter revenue that beat Wall Street estimates, helped by its AvKARE acquisition and new product launches.Net revenue in the fourth quarter of 2020 was $510M, an increase of 28% compared to $397M in the p...
Amneal Pharmaceuticals (AMRX) is surging with a ~6.3% gain in the pre-market today after its Q4 2020 earnings came ahead of analyst expectations.The company also announced the FDA approval for its Abbreviated New Drug Application ("ANDA") for Norelgestromin and Ethinyl Estradiol Tra...
News, Short Squeeze, Breakout and More Instantly...
Amneal Pharmaceuticals Inc. Class A Company Name:
AMRX Stock Symbol:
NASDAQ Market:
Amneal Pharmaceuticals Inc. Class A Website:
First presentation of preservative-free potassium phosphates in a single-dose IV infusion bag Third 505(b)(2) injectable added this year – will launch in third quarter Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) to...
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) announced today that the Company will release its second quarter 2024 financial results on Friday, August 9, 2024, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time. ...
FOCINVEZ (fosaprepitant) 150 mg/50 mL single dose vial is an anti-nausea agent for highly emetogenic and moderately emetogenic chemotherapy (HEC and MEC) Second injectable RTU product launched by Amneal in 2024 Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal”...